USP2 promotes cell migration and invasion in triple negative breast cancer cell lines. Qu Q,Mao Y,Xiao G,et al. Tumour Biology . 2015QING Qu; YAN Mao; GANG Xiao;.USP2 pro- motes cell migration and invasion in triple negative breast cancer cell lines.Tumor Biology.2015.5415-5423...
prognosis of patients remained largely unclear41. In addition, miR-9 was proposed to act as both tumor suppressor and oncogenic roles in breast cancers42,43. As for miR-9-3p, although less intensively investigated in breast cancer, it has been identified as a tumor suppressor in claudin-low ...
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2012;32:35–48. Google Scholar Pulaski BA, Ostrand‐Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2000;39:1–16. Article Google Scholar ...
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however, a proportion of patients have missed the surgical window at the time of diagnosis. TNBC...
Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines. J Cancer Res Clin Oncol. 2021;147:2923–33. Article PubMed PubMed Central Google Scholar Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L...
Triple negative breast cancer is more often responsive to chemotherapy than hormone receptor positive (ER+/PR+) breast cancer. On the other hand, long-term hormonal treatments (tamoxifen, aromatase inhibitors) used for ER+ subtypes are not effective for triple negative breast cancer since estrogen ...
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatmen
TNBC, triple-negative breast cancer; BC, breast cancer; BCT, conservative surgery; CHT, chemotherapy; DFS, disease-free survival; LR, local relapse; DR, distant relapse; RT, radiotherapy; OS, overall survival; CMF, cyclophosphamide–methotrexate–5-fluorouracil; BLBC, basal-like breast cancer; PF...
Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatmen
Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the development of resistance to chemotherapy affecting over 30% of patients. New therapeutics and companion biomarkers are urgently needed. Recognizing the elevated expression